These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26769569)

  • 1. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.
    Kruger S; Haas M; Ormanns S; Bächmann S; Siveke JT; Kirchner T; Heinemann V; Boeck S
    World J Gastroenterol; 2014 Aug; 20(31):10769-77. PubMed ID: 25152580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
    Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
    Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
    Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
    Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
    Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes.
    Manne A; Esnakula A; Sheel A; Sara A; Manne U; Paluri RK; He K; Yang W; Sohal D; Kasi A; Noonan AM; Mittra A; Hays J; Roychowdhury S; Malalur P; Rahman S; Jin N; Cloyd JM; Tsai S; Ejaz A; Pitter K; Miller E; Thanikachalam K; Dillhoff M; Yu L
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Advances in the Treatment of Metastatic Pancreatic Cancer.
    Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
    Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future biomarkers for pancreatic adenocarcinoma.
    Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
    Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
    Vuijk FA; de Muynck LDAN; Franken LC; Busch OR; Wilmink JW; Besselink MG; Bonsing BA; Bhairosingh SS; Kuppen PJK; Mieog JSD; Sier CFM; Vahrmeijer AL; Verheij J; Fariňa-Sarasqueta A; Swijnenburg RJ
    Sci Rep; 2020 Oct; 10(1):16211. PubMed ID: 33004930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
    Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
    Byrne JD; Jajja MR; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2200-5. PubMed ID: 26858448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
    Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
    Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
    Lemstrova R; Melichar B; Mohelnikova-Duchonova B
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer.
    Sullivan KM; Kozuch PS
    Cancer J; 2012; 18(6):633-41. PubMed ID: 23187852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.